Palvella Therapeutics Commences Phase 3 Portion of Phase 2/3 Pivotal Study of PTX-022 in Pachyonychia Congenita
Fast Track-designated program aims to be first targeted therapy addressing root cause of chronically debilitating rare genetic disease 

See more here